Shots:

• The US FDA has granted RMAT designation to AIC100 (ICAM-1 targeting & affinity-tuned LFA-1 binder CAR-T cell therapy) for treating recurrent anaplastic thyroid cancer (ATC)
• The designation was based on interim data, highlighted at ASCO 2024, from first 10 patients involved in P-I trial evaluating the safety, tolerability & RP2D of AIC100 to treat r/r poorly differentiated thyroid cancer (PDTC) & ATC
• As of the data cut off, results in 10 patients receiving AIC100 at 3 dose levels showed no DLTs with MTD not attained, DCR of 67% and ORR of 33% in DL2 (100 million CAR T cells) & DL3 (500 million CAR T cells) with 1 durable PR (DL2) & 1 ongoing durable mCR (DL3)

Ref: Businesswire | Image: AffyImmune

Related News:- Eli Lilly Receives the US FDA’s Approval for Retevmo (Selpercatinib) to Treat Thyroid Cancer or Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com